Research platforms

Research

 >>Research overview
 
 >>Research Areas
 
 >>Recent Achievements
 
 >>Research platforms
 
 >>Facilities
 
 >>Exchange & Collaboration

Research platforms

KeyLaboratory of Smart Drug Delivery, Ministry of Education

Brief Introduction

The Key Laboratory of Smart Drug Delivery Ministry of Education, referred to as the laboratory, was officially established in December 2010. In July 2013, it was received acceptance inspection by the Science and Technology Department of the Ministry of Education. In September 2016, it passed the assessment of the Ministry of Education. In June 2018, according to the requirements of the Ministry of Education, the laboratory carried out the re-election of the director, vice director and chairman of the academic committee. The new director is Professor Chen Jiang, and the vice directors are Professors Wei Wu and Wei Lu. The chairman of the academic committee is Professor Jian Ding, the academician of Chinese Academy of Science.

Aim and Direction

The laboratory relies on the national key disciplines of pharmaceutics at Fudan University, and integrates multidisciplinary research including polymer science, medicinal chemistry, pharmaceutical analysis, molecular imaging, and pharmacology to improve drug efficacy and reduce side effects. The laboratory includes four research directions: intelligent material design, targeted drug delivery, controlled drug release and evaluation of biological effect, forming a complete research system of smart drug delivery from material design, to targeted delivery and/or controlled release, to efficacy and safety evaluation.

The research of the laboratory focuses on actively targeted drug delivery system through molecular recognition, site-specific or controlled drug release in the lesion tissue according to the sensory response of the carrier material to the micro-environment or physiological changes of the body. The laboratory forms a forward-looking drug delivery technology that leads the development of the research field, and provides technical support and cultivates high-quality professionals for the research and product development of new drug delivery.

Projects and Achievements

The laboratory undertakes more than 200 national, provincial and ministerial level projects, including: 4 of 973 Projects, 2 of National New Drug Creation and Preparation Platform projects, 2 of 863 Projects, 58 from National Natural Science Foundation General Program, Key Program, Youth Program ; published 405 papers in SCI journals (18 ESI high-cited papers); 77 invention patents, 5 projects of new drug development, and won 30 awards from provincial and ministerial level including the first prize of Natural Science of Ministry of Education, won 2 national excellent doctoral dissertation awards and 11 Shanghai excellent doctoral dissertation awards.

The laboratory firstly proposed strategies for dual-level targeting and systemic targeting of major diseases in the brain; mimicked the natural properties of biological or biologically active substances to design biomimetic drug delivery systems; and developed the tumor microenvironment-smart responsive drug delivery systems based on the pathological features of tumor in development and progression. It has made breakthroughs in the concept and technological innovation of targeted drug delivery and smart drug delivery, and has made a contribution to bringing Chinese research to the forefront of the world in the field of smart drug delivery. The laboratory has made good progress in the key technology accumulation and new drug research and development including sustained release preparations for oral delivery, mucosal and transdermal drug delivery preparations, new Chinese medicines, and biomacromolecular drug formulations based on the "New Formulation and New Drug Delivery System Technology Platform", actively promoting the development of new drug formulations in China.

Teamwork and Conferences

There are 42 researchers in the laboratory (35 senior), including 2 principle investigators of the 973 Project and 12 more talent plan winners.

The laboratory hosted two sessions of the "China Pharmaceutical Preparation Conference" and a Sino-US joint international conference on the development trend of gene, cell therapy and drug delivery nanocarriers, which further expanded the domestic and international influence of the laboratory.

Laboratory Capabilities

The laboratory has 4,500 square meters of working space in the School of Pharmacy of Zhangjiang Campus of Fudan University. It has a national "New Drug and New Drug Release System Technology Platform", the State Administration of Traditional Chinese Medicine "Chinese Medicine Preparation Laboratory (Level 3)", "Pharmaceutical Preparation Pilot Laboratory", "Radioactive Tracer Technology Platform" and Large instrumentation valued more than 20 million yuan.

Centerfor Anti-Inflammation and Anti-Virus Drug Screening

Brief introduction

The center belongs to the Shanghai R&D Public Service Platform, and is also the important member of new drug R&D platforms for Fudan University School of Pharmacy.

Antiviral Drug Research Laboratory was established under the support and guidance of Prof. Wen Yumei in 1993. Since 2002, with continuous supports of National 211 and 985 Projects, the infrastructures and R&D capability have been greatly improved. In 2008, the Center for Anti-inflammation and Anti-virus Drug Screening formally became a sub-platform of the Shanghai R&D Public Service Platform.

Currently, our center has become the leading anti-viral drug screening and drug evaluation service platform in China and owns the powerful and comprehensive service capability, covering anti-virus, anti-bacterial and anti-inflammation drug evaluation. Especially for anti-virus drug screening, we have established the overall molecular, cellular and animal models for a series of viruses: Hepatitis B/C virus, HIV, Influenza and Coxsackie viruses, and so on.

In recent years, more than 5,000 compounds have been screened for universities, research institutes and enterprises, and efficacy evaluations for 7 drugs have been completed to assist enterprises in obtaining their clinical trial approvals.

Service aim

Becoming a first-class antiviral drug screening center in China, and committing to hatching Chinese novel antiviral drugs.

R&D public service capability

Staff composition:

The center currently has 10 full-time staff members, including 6 senior titles, many of whom have studied and worked in world-class anti-virus research laboratories.

Facilities:

ABSL 2 (P2 licensed) laboratory has 500 square meters for anti-viral cell experiments and 150 square meters of SPF-grade animal room for the virus-specific experiments. Our center owns all over regular equipment for virus-specific experiments.

Service Contents:

Anti-virus, anti-bacterial and anti-inflammation drug screening, new drug preclinical drug efficacy evaluation and mechanism exploring.

Anti-virus: HBV, Influenza, HSV, RSV, Coxsackie, EV71 virus assay (Major center: Antiviral Drug Research Laboratory)

HCV assay (Prof. Yuan zhenghong group, The Key Laboratory of Medical Molecular Virology)

HIV assay (Prof. Xu jianqing group, Shanghai Public Health Clinical Center affiliated to Fudan University)

Anti-bacterial: Staphylococcus aureus, Streptococcus pneumonia, Klebsiella pneumonia, Helicobacter pylori, and so on.

Anti-inflammation: Hepatitis (Chemically damaging hepatitis, Alcoholic hepatitis, No-alcoholic fatty hepatitis), Arthritis and enteritis.